Acute Migraine Relief: Nose-to-Brain Delivery with Lipid Nanoparticles

Migraine is a widespread and debilitating neurological condition, particularly affecting individuals under the age of 50. Current migraine treatments primarily rely on oral analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) for mild symptoms, while triptans or 5-HT1B/1D receptor agonists are used for moderate to severe cases. However, delivering these medications effectively poses a significant challenge due to the difficulty in crossing the blood-brain barrier, which restricts drug delivery to the brain. This limitation often leads to poor bioavailability and reduced therapeutic efficacy in migraine management.